Industry NewsmRNA therapeuticsmodernabiotech equities
Barclays Initiates Coverage Of Moderna Stock
5.9
Barclays initiated coverage of Moderna (NASDAQ:MRNA) on January 28 with an Equal Weight rating and a $25 price target, citing sector undervaluation and expected M&A activity that support a constructive 2026 outlook. Moderna reported approximately $1.0 billion in third-quarter 2025 revenue, held $6.6 billion in cash and investments, and guided year-end cash to $6.5–7.0 billion while continuing pipeline funding.
Key Points
- 1Initiates coverage with Equal Weight and $25 price target on Moderna on January 28.
- 2Cites sector undervaluation, expected M&A, and improving fundamentals driving a constructive 2026 outlook.
- 3Reports Q3 2025 revenue about $1.0B, $6.6B cash, guides year-end $6.5–7.0B; funds pipeline.
Scoring Rationale
Useful investor update with verified earnings and analyst coverage, but limited sector-wide novelty and shallow analysis.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems